The startup develops antibodies utilizing structure-based protein engineering and bioinformatics to create targeted cancer immunotherapies and treatments for autoimmune diseases. By enhancing the precision of therapeutic delivery, the company aims to improve patient outcomes in oncology and immunology.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional cancer immunotherapies and treatments for autoimmune diseases often lack precision, leading to suboptimal therapeutic delivery and potentially limiting patient outcomes. Existing approaches may not effectively target the tumor microenvironment or modulate immune responses with sufficient specificity.
Solution
Anwita Biosciences is developing a pipeline of optimized immunotherapeutics, including improved cytokines (Exenokines, Mableukins) and tumor-targeting antibody-drug conjugates (ADCs), designed for enhanced precision and efficacy. The company's core technology, integrating structure-guided AccuKine cytokine evolution and AccuBody discovery, enables the creation of fully optimized cytokine fusions and antibodies with superior therapeutic potential and favorable safety profiles. Anwita's portfolio includes half-life extended Exenokines, immune cell- or tumor cell-targeting Mableukines, and bi-functional Duoleukins, representing a new generation of immune therapies with broad applications in oncology and immunology. Their lead product, Exenokine-21 (JS014), a half-life extended IL-21, is currently in Phase 1 clinical trials.
Target Audience
Anwita Biosciences is focused on serving patients with cancer and autoimmune diseases, as well as biopharmaceutical companies seeking to partner and expand their pipelines with novel immunotherapeutics.
Features
- AccuKine cytokine evolution for optimized cytokine fusions
- AccuBody discovery of full-spectrum nanobodies and antibodies
- Half-life extension technology for improved cytokine exposure
- Tumor-targeting antibody-drug conjugate (ADC) platform
- Bispecific antibody technology for enhanced target specificity
- Proprietary topoisomerase inhibitor ATI020 for ADC payloads
- Pipeline of improved cytokines (Exenokines, Mableukins, Duoleukins)
- Programs in immuno-oncology, autoimmune, and inflammatory diseases